SYRS News and Press, Syros Pharmaceuticals Inc. From 04/09/19

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its previously announced concurrent underwritten public offerings of (i) 8,667,333 shares of its common stock and accompanying Class A warrants ...

Gainers:  Vital Therapies (NASDAQ: VTL ) +199% . JMU Limited (NASDAQ: JMU ) +24% . Aehr Test Systems (NASDAQ: AEHR ) +22% . GEE Group (NYSEMKT: JOB ) +19% . ChinaNet Online Holdings (NASDAQ: CNET ) +15% . RumbleON (NASDAQ: RMBL ) +15% . Hancock Jaffe Laboratories (NASDAQ: HJLI )...

Syros Pharmaceuticals (NASDAQ: SYRS ) has priced its public offerings of (i) 8,667,333 common shares and Class A warrants to purchase up to 1,951,844 common shares, at $7.50 per common share and warrant and (ii) 666 shares of Series A convertible preferred stock, convertible into 666,000 c...

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has priced its concurrent underwritten public offerings of (i) 8,667,333 shares of its common stock and accompanying Class A warrants to purchase up to...

Syros Pharmaceuticals (NASDAQ: SYRS ) launches two concurrent equity offerings, one comprised of stock and Class A warrants and the other Series A convertible preferred stock and Class A warrants. More news on: Syros Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, ...

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it is offering to sell, subject to market and other conditions, (i) shares of its common stock and Class A warrants to purchase common stock, and (ii) sha...

Presentations Highlight Syros’ Leadership in Selective CDK7 Inhibition as Potentially Transformative Targeted Approach for Difficult-to-Treat Cancers Alterations in RB Pathway Predictive of Response to SY-1365 in Ovarian Cancer Models, Supporting Further Evaluation as Potentia...

The following slide deck was published by Syros Pharmaceuticals, Inc. in conjunction with this Read more ...

Syros Pharmaceuticals (SYRS) Q4 2018 Earnings Conference Call March 7, 2019 08:30 AM ET Company Participants Naomi Aoki - VP, Corporate Communications and IR Dr. Nancy Simonian - CEO Dr. David Roth - Chief Medical Officer Joe Ferra - CFO Conference Call Participants Phi...

Syros Pharmaceuticals (NASDAQ: SYRS ): Q4 GAAP EPS of -$0.54 misses by $0.03 . More news on: Syros Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...